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Abstract Chronic liver disease results in a liver-scarring
response termed ﬁbrosis. Excessive scarring leads to cir-
rhosis, which is associated with high morbidity and
mortality. The only treatment for liver cirrhosis is liver
transplantation; therefore, much attention has been directed
toward therapies that will slow or reverse ﬁbrosis.
Although anti-ﬁbrogenic therapies have been shown to be
effective in experimental animal models, licensed therapies
have yet to emerge. A potential problem for any anti-
ﬁbrogenic therapy in the liver is the existence of the body’s
major drug metabolising cell (the hepatocyte) adjacent to
the primary ﬁbrosis-causing cell, the myoﬁbroblast. This
article reviews the development of a human recombinant
single-chain antibody (scAb) that binds to the surface of
myoﬁbroblasts. This antibody binds speciﬁcally to myoﬁ-
broblasts in ﬁbrotic mouse livers. When conjugated with a
compound that stimulates myoﬁbroblast apoptosis, the
antibody directs the speciﬁc apoptosis of myoﬁbroblasts
with greater speciﬁcity and efﬁcacy than the free com-
pound. The antibody also reduces the adverse effect of
liver macrophage apoptosis and—in contrast to the free
compound—reversed ﬁbrosis in the sustained injury model
used. These data suggest that speciﬁcally stimulating the
apoptosis of liver myoﬁbroblasts using a targeting antibody
has potential in the treatment of liver ﬁbrosis.
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Introduction
Fibrosis is a progressive disease characterised by the
accumulation of scarring extracellular matrix proteins,
which disrupt normal tissue architecture. As ﬁbrosis
worsens, tissue function is impaired and in vital organs
such as the liver—in the absence of transplantation—
morbidity and mortality results [1].
Fibrosis is caused by an expansion and an increase in the
activity of ﬁbroblast populations within the liver, which—
in a chronic damage setting—secrete and promote the
accumulation of extracellular matrix proteins [1]. Initial
work identiﬁed quiescent hepatic stellate cells as a source
of cells that cause ﬁbrosis [2], through their trans-differ-
entiation to myoﬁbroblasts (classically identiﬁed using
a-smooth muscle actin, Fig. 1). However, more recently it
has become clear that a distinct population of ﬁbroblasts
expand from the portal tract (periductal and portal), par-
ticularly when the region of damage is located to this part
of the lobule (e.g. in response to cholestasis) [3]. In addi-
tion, it has emerged that both these cell populations
originate, at least in part during chronic liver injury, from
the bone marrow [4, 5] and that ﬁbrogenic cells may even
be generated through epithelial-mesenchyme transition
[6, 7].
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At present, there are no therapies indicated for use as anti-
ﬁbrogenicsintheliver.Amajorhurdletothedevelopmentof
drugs for liver ﬁbrosis is the requirement for prolonged
treatment times to demonstrate efﬁcacy in clinical trials.
Triallengthobviouslyimposesgreatercostbutanadditional
disincentive exists that there is more chance for adverse
events to show during the trial. Failure in clinical drug trials
has major implications for pharmaceutical companies and
essentially dictates conservative investment decisions (par-
ticularly so in the case of liver disease, a high mortality area
and an exclusion criterion for most therapeutic trials). A
limited number of clinical trials are currently under way (for
review see [1]); in many cases, however, existing drugs
licensedforotherindications(egirbesartanandwarfarin[1])
have been used. Novel compounds require pre-clinical and
clinical safety testing and regulatory authorities require that
any new drug must signiﬁcantly beneﬁt patients. There are
fewerdrugsemergingtothepointofclinicaltrialaspotential
anti-ﬁbrogenics. One example, however, is the farnesoid X
receptor (FXR) activator 6-ethyl chenodeoxycholic acid
(INT-747).Thisnovelcompoundisknowntoinhibitboththe
trans-differentiation of human hepatic stellate cells to myo-
ﬁbroblasts in vitro and the development of ﬁbrosis in animal
models[8].INT-747iscurrentlyundergoingsafetytestingin
persons with type 2 diabetes with presumed fatty liver for
safety and tolerability [1].
In vitro models of liver ﬁbrosis (the spontaneous trans-
differentiation of hepatic stellate cells to myoﬁbroblasts in
culture [1]) and a range of in vivo animal models have aided
the identiﬁcation of potential therapeutic approaches for the
treatment of liver ﬁbrosis. Figure 2 illustrates the major
parameters affecting myoﬁbroblast activity and Table 1
lists some of the drug targets for therapeutic intervention.
A striking diversity of signalling pathways is available
for pharmacological intervention in myoﬁbroblasts. How-
ever, since recovery from ﬁbrosis is accompanied by the
apoptosis of liver myoﬁbroblasts [9], this laboratory has
concentrated on studying the effects of stimulating the
apoptosis of ﬁbrogenic cells in the liver as a potential
therapeutic approach for liver ﬁbrosis.
The fungal metabolite gliotoxin had originally been
shown to stimulate the apoptosis of leucocytes [10]. Glio-
toxin also stimulated the apoptosis of rat and human hepatic
stellate cells and liver myoﬁbroblasts in vitro [11, 12]. The
effects of gliotoxin in an animal model of liver ﬁbrosis
recovery (i.e. gliotoxin was administered after the ﬁnal liver
insult and the effects on the rate of ﬁbrosis reversal were
determined) indicated for the ﬁrst time that a promotion of
myoﬁbroblast apoptosis enhanced the resolution of ﬁbrosis
[11]. However, directing cell death as a mode of treatment
for a disease comes with risk because most therapeutics are
unlikely to act speciﬁcally on the target cells alone. The risk
is therefore the stimulation of cell death in cells other than
the target cells, with potential adverse effects.
Targeting myoﬁbroblasts
A number of targeting strategies are being evaluated for
their ability to selectively deliver therapeutics to liver
myoﬁbroblasts. These include modifying drug-carrying
Fig. 1 Histology of the cirrhotic human liver. Serial liver sections
from a liver biopsy were stained with (a) haematoxylin and eosin. (b)
immunochemically with an antibody to a-smooth muscle actin [11],
brown staining indicates liver myoﬁbroblasts. (c) Sirius red and
haematoxylin [11], red staining indicates extracellular matrix
deposition
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123proteins with mannose-6-phosphate for uptake via the
insulin-like growth factor II receptor [13], and with pep-
tides that recognise the collagen type VI [14] or platelet-
derived growth factor [15] receptors.
This article reviews the generation of a human recombi-
nant single-chain antibody (scAb—termed C1-3 [16]) to an
extracellularly exposed region of synaptophysin, a plasma
membrane protein expressed in the liver, speciﬁcally in
human and rodent myoﬁbroblasts [17]. Synaptophysin is
primarily associated with neural tissue and is thought to be
involved in synaptic vesicle exo-endocytosis. However,
synaptophysin knockout mice show no phenotype or
detectable effects on synaptic transmission [18]. An advan-
tageofusingsynaptophysinasatargettodelivertherapeutics
is that this protein forms part of an endocytosing vesicle,
increasingthelikelihoodforsigniﬁcantscAbandconjugated
therapeutic uptake in myoﬁbroblasts.
Phage display
Phage display is a powerful technique for selecting and
cloning sequences that encode proteins with a native afﬁnity
for a particular ligand [19, 20]. In the case of C1-3, a phage
library was employed in which potentially the entire human
repertoire of variable heavy and variable light chains (which
encode antibody antigen-binding sites) were cloned as
single fused domains into the pIII M13 bacteriophage coat
protein gene (Fig. 3a). Each phage ‘‘displays’’ a variable
domain on its surface, with typically[10
7 different clones
comprising a phage display library. Variable domains that
interact with a particular antigen (for C1-3, the antigen is
the peptide 2 sequence—see Fig. 4) can be selected by a
process of ‘‘panning’’, whereby the phage is exposed to an
immobilised target sequence. Unbound phage is removed
by washing and bound phage is eluted and ampliﬁed
through re-infection of Escherichia coli (Fig. 3b). The
process of panning is repeated several times allowing for
the isolation of speciﬁc high-afﬁnity antigen-binding phage.
Single clones are then isolated and analysed prior to sub-
cloning heavy and light chain-encoding regions into an
expression vector that generates a single-chain protein (i.e.
scAb) fused in frame with other domains that facilitate
detection and puriﬁcation. Using established procedures,
such as protein tagging, high levels of pure monoclonal
scAb can be generated with relative ease.
C1-3 scAb
A range of human recombinant scAbs were generated to
synaptophysin by phage display [16]. One of these, C1-3,
was selected and its ability to act as a targeting agent for
liver myoﬁbroblasts was examined. Fluorescently labelled
C1-3 scAb avidly bound to human myoﬁbroblasts (Fig. 5)
but not human hepatocytes [16]. The C1-3 was taken up
into myoﬁbroblasts through pinocytosis and alone was not
toxic to myoﬁbroblasts in vitro, but when conjugated with
tributyl tin, the scAb directed the toxin to myoﬁbroblasts
(with toxin activity retained) [16].
Mice with liver ﬁbrosis (via carbon tetrachloride
administration) were injected intraperitoneally with C1-3
Fig. 2 Schematic diagram
outlining the major parameters
affecting the severity of liver
ﬁbrosis and the major points at
which potential anti-ﬁbrogenic
therapeutics intervene. Numbers
refer to numbering for ‘‘mode of
action’’ as given in Table 1.
Inhibition, T; promoters, :
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123Table 1 The major drug targets for potential anti-ﬁbrogenic drugs
Mode of action Targeting Potential therapeutic agents and comments
1 Preventing primary
cause of disease
Undoubtedly, preventing or curing the primary cause of disease is the best way to prevent or treat
liver ﬁbrosis. Anti-ﬁbrogenics are required when the primary cause of disease is not
successfully treated.
2 Antioxidants Reactive oxygen
species released
from inﬂammatory
cells (also possibly
myoﬁbroblast
proliferation).
N-acetyl cysteine [31, 32], resveratrol [32], quercetin [32]. Note, quercetin is also a WNT
signalling inhibitor (Tcf/Lef inhibitor) [33] and a repression of WNT signalling has been
associated with trans-differentiation to myoﬁbroblasts [34, 35]. Vitamin E [36], evidence of
anti-ﬁbrogenic effects in patients with NASH treated with vitamins C and E [37]. Angiotensin
II inhibitors—via inhibiting the activation of NADPH oxidase mediated by angiotensin II [38].
3 Anti-inﬂammatory
agents
Glucocorticoid
receptor
Glucocorticoid agonists often administered to inhibit inﬂammation, particularly in immune-
mediated hepatitis [39]. May not have any direct effects on ﬁbrosis [40] but dexamethasone has
been noted to inhibit TGFb expression in liver myoﬁbroblasts in vitro [41]. Note, Kupffer cell-
targeted glucocorticoids lead to increased levels of ﬁbrosis in experimental animal models [42].
Cyclooxygenase Cyclooxygenase (COX) inhibitors inhibit the production of leukotrienes and prostaglandins, e.g.
COX2 inhibitor JTE-522 [43]. However, hepatic COX2 knockout or overexpression in
transgenic mice is reported to have no effects on liver ﬁbrosis [44].
NF-jB. NF-jB inhibitors (e.g. sulfasalazine [45]). However, primary effects believed to be mediated via
apoptosis (see 5).
4 Proliferation
inhibitors
Peroxisome
proliferator
activated receptor-
c (PPARc).
PPARc agonists—such as anti-diabetic thiazolidones (e.g. troglitazone, rosiglitazone,
pioglitazone—inhibit trans-differentiation/proliferation of myoﬁbroblasts in vitro [46, 47].
PPARc is expressed in hepatic stellate cells but falls rapidly in primary culture as the cells
trans-differentiate to myoﬁbroblasts [47].
Farglitazar is completing an anti-ﬁbrogenic trial in patients with chronic hepatitis C[1]. Curcumin
effects may also function via PPAR c [48].
Farnesoid X receptor
(FXR).
FXR activator synthetic bile acid INT-747 is anti-ﬁbrogenic [8] although effects could also be
mediated via PXR since this related receptor also ligands bile acids [49]. Currently undergoing
clinical trial [1].
Pregnane-X receptor
(PXR).
PXR ligands (e.g. rifampicin, hyperforin) inhibit proliferation and ECM synthesis [50, 51].
Rifampicin is often given to patients with primary biliary cirrhosis (to control itch) and has
been shown to reduce serum levels of alkaline phosphatase in patient trials [52, 53]. However,
its effects on ﬁbrosis have not been examined. Ursodeoxycholate is also a PXR activator [54].
This compound is also given to patients with primary biliary cirrhosis and has been reported to
reduce progression to cirrhosis [55].
Renin-angiotensin
system
Liver myoﬁbroblasts synthesise angiotensin, which acts in an autocrine manner to promote
ﬁbrosis [56]. Angiotensin II R1 antagonists (e.g. losartan) inhibit proliferation and also ECM
synthesis [57] and have been reported to reduce ﬁbrosis in clinical trails [58]. The angiotensin
II R1 antagonist irbesartan is currently undergoing clinical trials [1]. Angiotensin-converting
enzyme (ACE) inhibitors are also potential therapeutics, (e.g. perindopril [59]).
Phosphodiesterase Pentoxifylline has been shown to inhibit liver ﬁbrosis in animal models [60, 61]. Pentoxifylline is
an inhibitor of phosphodiesterases, leading to increased intracellular levels of cyclic adenosine
monophosphate (cAMP) [62], but may act by other mechanisms [63]. Undergoing clinical trials
for survival rate in patients with cirrhosis [1].
MAP kinase Salvianolic acid [64], but may have other targets [65]. Reported to inhibit ﬁbrosis in a cohort of
patients with hepatitis B [66].
Unknown Pirfenidone [67]. In relation to the mechanism of the anti-ﬁbrotic action, pirfenidone has been
shown to modify cytokine regulatory actions, inhibit ﬁbroblast proliferation and collagen
matrix synthesis. Shown to be effective in clinical trials [1]. Halofuginone inhibits
myoﬁbroblast proliferation by unknown mechanism [68, 69] and also by other mechanisms
(see 6 and 8).
CB1 receptor CB1 receptor is expressed in myoﬁbroblasts and promote ﬁbrosis [70]. CB1 antagonism (e.g. via
SR141716A/rimonabant) inhibits ﬁbrosis [70], also increases myoﬁbroblast apoptosis [70].
CB2 receptor CB2 receptor agonists (e.g. D9-tetrahydrocannabinol [71]). Note, however, that daily cannabis
smoking is associated with ﬁbrosis progression [72].
Opioid receptor Opioid receptor antagonists (e.g. naltrexone [73]).
Serotonin (5HT)
receptor
Rodent and human myoﬁbroblasts express several 5HT receptor sub-types; 5HT2 antagonists are
anti-ﬁbrogenic (e.g. methiothepin maleate or spiperone [74]). Also increases myoﬁbroblast
apoptosis [74].
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123scAb to determine its effectiveness as a drug-targeting
agent in vivo [21]. Initial studies used ﬂuorescently label-
led C1-3 to examine its distribution throughout the body up
to 24 h after injection. The results of these studies showed
that the C1-3 scAb appeared in the serum within 20 min
and was eliminated with an approximate half life of 2 h
[21]. The C1-3 scAb was detectable in liver homogenate
but undetectable in brain, muscle or spleen [14]. Immu-
nohistochemical analysis indicated that the C1-3 scAb
localised to the liver, in regions where scars were present.
There was minimal immunohistochemical evidence for the
presence of C1-3 scAb in non-ﬁbrotic liver [21]. Co-
staining of ﬁbrotic liver sections showed that the C1-3
scAb colocalised with myoﬁbroblast a-smooth muscle
actin, but not the monocyte and macrophage marker F4/80
[21]. These data indicate that the C1-3 scAb readily and
selectively targeted liver myoﬁbroblasts in an animal
model of liver ﬁbrosis.
To determine whether C1-3 could deliver a functional
experimental anti-ﬁbrogenic therapeutic agent to myoﬁ-
broblasts, it was chemically conjugated with gliotoxin.
Free gliotoxin has been shown in previous work to stim-
ulate the apoptosis of liver myoﬁbroblasts in vitro and in
vivo and enhance recovery from liver ﬁbrosis in vivo [11,
12, 22]. However, gliotoxin also causes—although to a
lesser degree—the apoptosis of hepatocytes and stimulates
Kupffer cell death [4, 17, 23, 24].
Gliotoxin was chemically conjugated to either a C1-3
scAb or a control CSBD9 scAb (selected for its ability to
bind to an irrelevant ligand) using N-[p-maleimidophenyl]
isocyanate and S-acetyl thioglycolic acid N-hydroxy-
succinimide [21] (for details also see online data:
http://dx.doi.org/10.1016/j.jhep.2008.01.032). Conjugation
did not signiﬁcantly alter scAb afﬁnities for their respective
antigens (as determined using antigen ELISA and BIAcore
Table 1 continued
Mode of action Targeting Potential therapeutic agents and comments
5 Pro-apoptotics NF-jB Through inhibition of activation via IKK inhibition (e.g. sulphasalazine [45]), also proteasomal
inhibitors [75]. Note, human liver myoﬁbroblasts may become more resistant to proteasomal
inhibitors with time [76]. Gliotoxin inhibits NF-jB via proteasomal inhibition [12], however, it
also targets mitochondria [45], which may explain its potency at stimulating human
myoﬁbroblast apoptosis [11, 76] and inhibition of ﬁbrosis in vivo [11, 21].
RS kinase RS kinase inhibition promotes myoﬁbroblast apoptosis and inhibits liver ﬁbrosis in animal models
[77].
CB1 and CB2
receptors (see 4)
5HT receptors
(see 4)
6 ECM synthesis
inhibitors
TGFb TGFb antagonism (e.g. decoy soluble TGFb receptor [78]), However, TGFb may be critical for
other tissues and may be a tumour supressor [79]. Inhibitors of proteolytic TGFb activation
(e.g. camostat mesilate [80]). Halofuginone [81].
7 Anti-protease
inhibitors
Tissue inhibitors of
metalloproteinases
(TIMP).
Polaprezinc down regulates TIMP1 and 2 expression [82]. Antagonistic antibodies [83].
8 Pro-proteases uPA via adenoviral gene therapy in animal model [84]. Halofuginone increases ﬁbrolytic MMP
expression [69, 85].
The table outlines some of the potential anti-ﬁbrogenic drug targets for which potential therapeutic agents are already available. There are
additional pathways for which either intervention remains unexploited or information is not freely available. These include intervening in
adiponectin signalling, which suppresses PDGF-dependent myoﬁbroblast proliferation and ﬁbrosis in experimental animal models [86], and
leptin, which is synthesised by myoﬁbroblasts [87] and promotes ﬁbrosis [88]
Fig. 3 (a) Schematic diagram of recombinant M13 bacteriophage
incorporating an scAb within its coat protein. (b) Schematic diagram
outlining the procedure of phage display
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blast apoptosis (see Figs. 6 and 7).
Mice were administered carbon tetrachloride twice
weekly for 8 weeks to generate liver ﬁbrosis. During the
last week prior to the ﬁnal injection of carbon tetrachloride,
mice were treated with a single dose of C1-3 scAb or C1-3-
gliotoxin scAb. The mice were therefore treated with a
potential therapeutic agent and injury was sustained by
further treatment with carbon tetrachloride. Fibrotic mice
were also treated with an equivalent dose of free gliotoxin
or gliotoxin conjugated to CSBD9 (i.e. CSBD9-GT).
Fig. 4 Schematic diagram of
synaptophysin. Each circle
represents an amino acid, with
membrane-spanning residues
determined using TMpred
software [16]. Orange residues
correspond to the antigen site
for C1-3
Fig. 5 Human liver myoﬁbroblasts bind FITC-labelled C1-3 scAb
(green). Hepatic stellate cells were isolated by pronase and collage-
nase perfusion from resected human liver and were cultured as
outlined [11]. After transdifferentiation and sub-culture, cells were
typically more than 95% positive for the classic myoﬁbroblast marker
a-smooth muscle actin [1]. The panel shows a typical view of liver
myoﬁbroblasts after incubation with FITC-labelled C1-3 (green) in
culture as outlined [16], followed by ﬁxation and co-staining for the
myoﬁbroblasts marker a-smooth muscle actin (red) and DNA using
DAPI (blue)
Fig. 6 Time course for the effects of free gliotoxin or C1-3-gliotoxin
(C1-3-GT) on sub-stratum adherence in vitro. Human myoﬁbroblasts
(culture-activated hepatic stellate cells [11]) were sub-cultured into
24-well plates in 300 ll of medium and treated with either free
gliotoxin added from a 1,000-fold molar concentrated stock in DMSO
vehicle (total 450 pmoles/well); 4.5 lg C1-3/well or 4.5 lg C1-3-
gliotoxin scAb (to give approximately 450 pmoles gliotoxin/well for
conjugated scAb). Data are the mean and standard deviation of 3
separate human cell preparations. Right panels, photomicrographs of
typical views of cells at the indicated treatment after 5 h
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free gliotoxin reduced the number of myoﬁbroblasts but
did not reduce ﬁbrosis severity in the liver. C1-3-gliotoxin
more potently reduced the number of myoﬁbroblasts
present than the same dose of free gliotoxin and in addition
signiﬁcantly reduced the severity of ﬁbrosis in the liver.
C1-3 scAb, CSBD9 scAb and CSBD9-GT had no effect on
the number of liver myoﬁbroblasts or ﬁbrosis severity.
Interestingly, free gliotoxin reduced the number of F4/80
positive cells (i.e. monocytes and macrophages/Kupffer
cells) and matrix metalloproteinase 13 levels in the liver,
whereas C1-3-gliotoxin did not. Macrophage depletion
abrogates recovery from liver ﬁbrosis [25]. Retaining
macrophages in C1-3-gliotoxin-treated animals may
account for the improved anti-ﬁbrogenic effect of gliotoxin
when targeted to liver myoﬁbroblasts with C1-3.
Diagnostic and therapeutic perspectives
Two major hurdles must be overcome to advance suc-
cessful treatments for ﬁbrosis. The ﬁrst is the effective
assessment of ﬁbrosis in both experimental and clinical
studies. It remains problematic to accurately screen for
ﬁbrosis using a battery of serum markers, particularly for
those at early and intermediate stages of disease [26].
Biopsy remains the ‘‘gold standard’’ diagnostic tool for
liver disease [27] but has signiﬁcant drawbacks (the
Fig. 7 Time course for the
effects of C1-3-GT on active
caspase 3 levels in human
myoﬁbroblasts in vitro. Human
myoﬁbroblasts were cultured
and treated with C1-3-GT
essentially as outlined in
Figure 5. At the indicated time
points, cells were ﬁxed and
stained for a-smooth muscle
actin (red), active caspase 3
(green) and DNA using DAPI
(blue). The active caspase 3
antibody was purchased from
Promega (Southampton, UK).
Results are typical of cells
isolated from 3 individual
patients
Table 2 The effects of gliotoxin and C1-3-gliotoxin on parameters of liver ﬁbrosis in a sustained carbon tetrachloride model of liver ﬁbrosis [21]
Treatment Number of myoﬁbroblasts Number of F4/80 cells Fibrosis severity MMP-13 levels
DMSO vehicle ????? ??? ???? ????
Free gliotoxin ???
a ??
a ???? ???
a
PBS ????? ??? ???? ????
C1-3
C1-3-gliotoxin ?
b ??? ??
b ????
CSBD9 ????? ??? ???? ????
CSBD9-gliotoxin ????? ??? ???? ????
Mice were administered CCl4 over a 8-week period as outlined [21] and the liver was examined for myoﬁbroblasts via a-smooth muscle actin
immunostaining [11]; Kupffer cells by immunostaining for F4/80 [21]; ﬁbrosis severity through histochemical staining with Sirius red [11]; and
MMP-13 levels by immunohistochemistry [21]. Note, gliotoxin was administered in DMSO at a dose of 0.6 mg/kg body weight. ScAbs were
administered in phosphate-buffered saline (PBS) at a dose of 20 mg of protein/kg body weight. Mice received conjugates at an equivalent dose of
0.6 mg of gliotoxin/kg body weight. Data are blinded examination of staining intensity in liver sections from ﬁve animals per treatment group—
signiﬁcantly different (two tailed) from
aDMSO control or
bPBS control using Student’s T test (P[95%) [21]
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123procedure is risky; repeated biopsy is inadvisable; and it
does not give a globally accurate picture of organ ﬁbrosis).
The second hurdle is speciﬁcity and efﬁcacy of potential
treatments (in the liver, the myoﬁbroblasts lie adjacent to
the major drug metabolising cell of the body, the
hepatocyte).
This laboratory has examined the potential of an anti-
body-based approach to tackle both imaging and
therapeutic delivery in ﬁbrosis. Although the C1-3 scAb
does not directly bind to ﬁbrosis proteins (it binds to the
major ﬁbrogenic cell), an image-visible scAb derivative
may be effective in providing an indication of ﬁbrosis
severity. If successful as an imaging agent, experimental
and clinical imaging studies should aid in its development
as a targeting agent for anti-ﬁbrogenic therapeutics.
The utility or therapeutic efﬁcacy of whole antibody, or
related antibody structures, in vivo is inﬂuenced by a
number of competing factors. These include speciﬁcity,
afﬁnity (including avidity) and serum half life. The C1-3
has already been expressed successfully as a monomeric
scAb (37 kDa). In addition, it could also be used in a
slightly smaller but related scFv formulation (25 kDa) or
expressed as a dimeric fragment (60 kDa, which will typ-
ically show one order of magnitude improvement in
afﬁnity for antigen through increased avidity). Finally, the
C1-3 could be expressed as a full (150 kDa) mAb incor-
porating either a mouse or a human Fc region. This
construct will have a similar afﬁnity to the C1-3 dimer but
an increased serum half life and the capacity to initiate cell
killing upon binding in vivo.
Typically, for imaging agents, a shorter serum half life
is favoured, to maximise signal-to-noise ratios in the dis-
eased tissue. For therapeutic applications, a whole antibody
is often preferred where antibody binding and presentation
of the Fc region can recruit components of the mammalian
immune system and induce cell killing. However, for cer-
tain applications, a smaller antibody fragment conjugated
to a cell-killing agent may be a more potent therapeutic
formulation. This type of agent can provide a powerful
alternative to Fc-induced cell death, offering greater tissue
penetration and rapid clearance of toxic drugs from non-
target tissues.
Theadministrationofarecombinantantibodyspeciﬁcfor
thesurfaceoflivermyoﬁbroblastscouldbeusedtodevelopa
safer,lessinvasiveandmoreeffectivediagnostictoolforthe
assessment of ﬁbrosis throughout the entire organ. In the
short term, this could lead to more reﬁned experimental
animal studies; provide a more effective assessment of
potentialanti-ﬁbrogenics;and reduce the numberof animals
requiredinpre-clinical studies.Experimentalanimal studies
will also contribute to the translation of the diagnostic to the
clinical reality in the long term, as part of in vivo imaging
(diagnosticanddiseasesmanagement). Inaddition,theC1-3
antibody could be used to direct anti-ﬁbrogenics to the
myoﬁbroblasts (or analogous pro-ﬁbrogenic cells in other
tissues). Directing therapeutics speciﬁcally to the target
myoﬁbroblast—and away from other cells—will enhance
the efﬁcacy of an anti-ﬁbrogenic since it will reduce the
amountoftherapeuticrequiredandthe likelihoodofadverse
effects. However, a drawback of using C1-3 is the potential
effect on any cells that also express synaptophysin, partic-
ularly when the conjugated therapeutic mediates cell death.
The major concern would therefore be neural and neuroen-
docrine cells. Although there is no evidence that the C1-3
scAb crossed the blood-brain barrier in animal studies [21],
imaging studies should conﬁrm whether this is the case.
However,itshouldbeborneinmindthatthereiscurrentlyno
treatments available for use as anti-ﬁbrotic in patients [28].
The major causes of liver ﬁbrosis in the developed world are
non-alcoholic steatohepatitis (NASH), hepatitis C infection
andalcoholism. NASH hasan incidenceofatleast 2% inthe
European Union and United States and the incidence of
Hepatitis C infection is between 1% and 2% [29, 30]. The
incidence of both of these diseases is predicted to rise in the
future and further reinforces the urgent need to diagnose,
manage and treat this ‘‘silent killer’’. It may be the case with
some patients with cirrhosis—in whom there are no thera-
peutic options available—that an experimental and more
risky approach may be needed in order to ﬁnd effective
treatments.
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